Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity

Journal of Immunotherapy

Volumn 34, Issue 1, 2011, Pages 1-15

  Fotin Mleczek, Mariola ^a   Duchardt, Katharina M ^a   Lorenz, Christina ^a   Pfeiffer, Regina ^a   Ojkić Zrna, Sanja ^a   Probst, Jochen ^a   Kallen, Karl Josef ^a  

^a CureVac GmbH   (Germany)

Author keywords

adjuvant; cancer vaccine; immunotherapy; ribonucleic acid; RNActive

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; OVALBUMIN VACCINE; PROSTATE SPECIFIC MEMBRANE ANTIGEN VACCINE; PROTAMINE; RNA VACCINE; STEAP VACCINE; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPLEX FORMATION; CYTOKINE RELEASE; DRUG DESIGN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PROTAMINES; RNA, MESSENGER; VACCINES, SYNTHETIC;

EID: 78650640612     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181f7dbe8     Document Type: Article

References (28)

1. Greenland JR, Letvin NL. Chemical adjuvants for plasmid DNA vaccines. Vaccine. 2007;25:3731-3741.
2. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell. 2006;124:849-863.
3. Weide B, Carralot J, Reese A, et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother. 2008;31:180-188.
4. Pascolo S. Messenger RNA-based vaccines. Expert Opin Biol Ther. 2004;4:1285-1294.
5. Scheel B, Braedel S, Probst J, et al. Immunostimulating capacities of stabilized RNA molecules. Eur J Immunol. 2004; 34:537-547.
6. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303:1526-1529.
7. Diebold SS, Kaisho T, Hemmi H, et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303:1529-1531.
8. Scheel B, Teufel R, Probst J, et al. Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol. 2005;35:1557-1566.
9. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949 Pt 1): 1465-1468.
10. Hoerr I, Obst R, Rammensee HG, et al. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 2000;30:1-7.
11. Granstein RD, Ding W, Ozawa H. Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. J Invest Dermatol. 2000;114:632-636.
12. Hess PR, Boczkowski D, Nair SK, et al. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol Immunother. 2006;55: 672-683.
13. Conry RM, LoBuglio AF, Wright M, et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. 1995;55:1397-1400.
14. Carralot J, Probst J, Hoerr I, et al. Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol Life Sci. 2004;61:2418-2424.
15. Zhou WZ, Hoon DS, Huang SK, et al. RNA melanoma vaccine: induction of antitumor immunity by human glyco-protein 100 mRNA immunization. Hum Gene Ther. 1999;10: 2719-2724.
16. Lacelle MG, Jensen SM, Fox BA. Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. Clin Cancer Res. 2009;15: 6881-6890.
17. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9:162-174.
18. Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111:4233-4244.
19. Prud'homme GJ. DNA vaccination against tumors. J Gene Med. 2005;7:3-17.
20. Donnelly J, Berry K, Ulmer JB. Technical and regulatory hurdles for DNA vaccines. Int J Parasitol. 2003;33:457-467.
21. Radcliffe JN, Roddick JS, Stevenson FK, et al. Prolonged antigen expression following DNA vaccination impairs effector CD8+ T cell function and memory development. J Immunol. 2007;179:8313-8321.
22. Probst J, Weide B, Scheel B, et al. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther. 2007;14:1175-1180.
23. Gust TC, Zenke M. RNA transfer and its use in dendritic cell-based immunotherapy. Expert Opin Biol Ther. 2005;5:173-181.
24. Wang R. Regulatory T cells and toll-like receptors in cancer therapy. Cancer Res. 2006;66:4987-4990. (Pubitemid 43844916)
25. Renn CN, Sanchez DJ, Ochoa MT, et al. TLR activation of Langerhans cell-like dendritic cells triggers an antiviral immune response. J. Immunol. 2006;177:298-305.
26. Prlic M, Bevan MJ. Exploring regulatory mechanisms of CD8+ T cell contraction. Proc Natl Acad Sci USA. 2008;105: 16689-16694.
27. Gao FG, Khammanivong V, Liu WJ, et al. Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res. 2002;62:6438-6441.
28. Makki A, Weidt G, Blachere NE, et al. Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor. Cancer Immun. 2002;2:4.